Sava Infond D.O.O. Sarepta Therapeutics, Inc. Transaction History
Sava Infond D.O.O.
- $566 Billion
- Q4 2024
A detailed history of Sava Infond D.O.O. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Sava Infond D.O.O. holds 3,000 shares of SRPT stock, worth $329,430. This represents 0.06% of its overall portfolio holdings.
Number of Shares
3,000Holding current value
$329,430% of portfolio
0.06%Shares
1 transactions
Others Institutions Holding SRPT
# of Institutions
529Shares Held
85.7MCall Options Held
1.74MPut Options Held
1.35M-
Black Rock Inc. New York, NY10.3MShares$1.13 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$998 Million0.02% of portfolio
-
Capital International Investors Los Angeles, CA6.26MShares$687 Million0.16% of portfolio
-
Janus Henderson Group PLC London, X04.36MShares$479 Million0.29% of portfolio
-
State Street Corp Boston, MA4.27MShares$469 Million0.02% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $9.62B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...